Yan W
Hospital of Blood Diseases, Tianjin.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1991 Oct;13(5):317-22.
Seven patients with acute myeloid leukemias (AML) in complete remission (CR) were treated with high dose chemotherapy and/or total body irradiation (TBI) followed by autologous bone marrow transplantation (ABMT). The clinical status of the 7 cases at ABMT were as follows: 5 in CR1 (2 with standard risks and 3 with high risks) and 2 in CR2 (both with standard risks). The conditioning regimens used for ABMT were cyclophosphamide plus TBI in 3 cases, high dose busulfan plus cyclophosphamide in 3 cases, and BACT program chemotherapy in 1 case. All 7 cases showed hemopoietic reconstitution after ABMT; no death occurred within the post-transplantation aplasia period, but hepatotoxicity was observed with high dose busulfan. Up to December, 1989, 2 patients in CR1 with standard risk receiving transplants had survived, disease free, for 26 and 18 months, respectively; one of 2 patients in CR2 with standard risk receiving transplants had survived for 30 months, and the other died at the 9th month after ABMT with no sign of leukemia relapse. Two of the 3 patients with high risk relapsed at 5 months post-ABMT and the third was in continuous CR for 5.5 months.
7例急性髓细胞白血病（AML）完全缓解（CR）患者接受了大剂量化疗和/或全身照射（TBI），随后进行自体骨髓移植（ABMT）。这7例患者在进行ABMT时的临床状况如下：5例处于CR1期（2例为标准风险，3例为高风险），2例处于CR2期（均为标准风险）。用于ABMT的预处理方案中，3例采用环磷酰胺加TBI，3例采用大剂量白消安加环磷酰胺，1例采用BACT方案化疗。所有7例患者在ABMT后均出现造血重建；移植后骨髓抑制期内无死亡发生，但大剂量白消安观察到有肝毒性。截至1989年12月，2例处于CR1期且接受移植的标准风险患者分别无病存活了26个月和18个月；2例处于CR2期且接受移植的标准风险患者中，1例存活了30个月，另1例在ABMT后第9个月死亡，无白血病复发迹象。3例高风险患者中有2例在ABMT后5个月复发，第3例持续CR 5.5个月。
